Stay updated with breaking news from Carbohydrate Binding Molecule. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
/PRNewswire/ -- Pneumagen, a clinical stage biotech company developing Neumifil, a broad-spectrum antiviral, intranasal drug for the prophylaxis and treatment...
/PRNewswire/ -- Pneumagen, a clinical stage biotech company developing Neumifil, a broad-spectrum antiviral, intranasal drug for the prophylaxis and treatment...
/PRNewswire/ -- Pneumagen, a clinical stage biotech company developing Neumifil, an intranasal, broad-spectrum antiviral treatment to prevent or, if infected...
- Neumifil is a novel broad-spectrum anti-viral product that was shown to be well-tolerated with no safety signals at all doses tested - Pneumagen plans to conduct a Phase 2 Influenza challenge
/PRNewswire/ -- Pneumagen, a clinical stage biotech company developing Neumifil, a novel intranasal spray which is designed to provide patients at risk with an...